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Abstract Recent data show that a strong relation exists in
certain cells between mitochondria and caspase activation in
apoptosis. We further investigated this relation and tested
whether treatment with the permeability transition (PT)-inducing
agent atractyloside of Percoll-purified mitochondria released a
caspase-processing activity. Following detection of procaspase-
11 processing, we further purified this caspase-processing
protease and identified it as cathepsin B. The purified cathepsin
B, however, was found to be derived from lysosomes which were
present as minor contaminants in the mitochondrial preparation.
Besides procaspase-11, caspase-1 is also readily processed by
cathepsin B. Procaspase-2, -6, -7, -14 are weak substrates and
procaspase-3 is a very poor substrate, while procaspase-12 is no
substrate at all for cathepsin B. In addition, cathepsin B induces
nuclear apoptosis in digitonin-permeabilized cells as well as in
isolated nuclei. All newly described activities of cathepsin B,
namely processing of caspase zymogens and induction of nuclear
apoptosis, are inhibited by the synthetic peptide caspase
inhibitors z-VAD.fmk, z-DEVD.fmk and to a lesser extent by
Ac-YVAD.cmk.
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1. Introduction
Apoptosis is a physiological, morphologically distinct form
of programmed cell death that occurs in all multicellular or-
ganisms and plays a crucial role during embryonic develop-
ment, in immune cell responses and in tissue homeostasis.
Inappropriate apoptosis is associated with serious diseases
and disorders including neurodegenerative disorders, AIDS
and cancer [1]. Two phenomena that have emerged in apop-
tosis research in the most recent years are the activation of
caspases, a class of intracellular aspartate-speci¢c cysteinyl
proteases (for reviews see [2] and [3]), and the involvement
of mitochondria in the signaling pathway leading to apoptosis
(for reviews see [4] and [5]).
Caspases have been recognized as central executors of
apoptosis. They are currently divided into initiator and execu-
tioner caspases. Initiator caspases (e.g. caspase-8) are acti-
vated as a consequence of cell membrane signaling events,
while executioner or e¡ector caspases (e.g. caspase-3) are re-
sponsible for the cleavage of crucial substrates involved in the
apoptotic degradation phase. Some caspases, such as caspase-
1 (ICE), which processes pro-interleukin-1L and pro-interleu-
kin-18 into their mature form, and murine caspase-11, re-
quired for the activation of caspase-1 [6], also play an impor-
tant role in in£ammatory responses.
Caspases are synthesized as inactive zymogens, known as
procaspases, with a tripartite structure consisting of an N-
terminal prodomain of variable length, and a large and small
subunit, called the p20 and p10 subunits, respectively. Proc-
essing of procaspases into the mature heterotetramer product
(p20p10)2 requires cleavage after aspartic acid (Asp) residues
located in the interdomain linkers of the protein. This proteo-
lytic activation may occur through autoprocessing, as is the
case after oligomerization of procaspase-8 [7,8], or through
cleavage by other caspases in a hierarchical manner and
thus creating a protease cascade. Such a caspase cascade is
found in the Fas pathway where it starts with recruitment of
procaspase-8 to the death-inducing signaling complex (DISC)
[9] and propagates into activation of caspase-3 [10]. However,
other proteases can also activate caspase zymogens. Gran-
zyme B, which is the only other mammalian protease that
shares the caspase primary speci¢city for Asp, cleaves procas-
pase-3 to active caspase-3 [11,12], and the non-Asp-speci¢c
protease cathepsin G can generate active caspase-7 [13].
Therefore, it seems that the proteolytic-sensitive caspase inter-
domain linkers may allow non-Asp-speci¢c proteases such as
those from lysosomes to engage the apoptotic apparatus
under pathological conditions.
The ¢rst direct evidence for involvement of mitochondria in
apoptosis came from a cell free system based on Xenopus
laevis egg extracts, where it was shown that nuclear apoptotic
events occurred only in the presence of the mitochondrial
fraction [14]. Release of cytochrome c [15,16] and other pro-
apoptogenic components ^ such as the as yet unidenti¢ed 50-
kDa apoptosis inducing factor (AIF) [17] ^ are induced by the
opening of pores in the inner membrane of mitochondria, a
condition known as permeability transition (PT). The opening
of these pores allows the equilibrium of ions and respiratory
substrate between cytosol and mitochondrial matrix leading to
a decrease in the mitochondrial membrane potential and ar-
rest of ATP synthesis [18]. Cytochrome c release does not
always require induction of PT [19] and is prevented by over-
expression of Bcl-2 [20]. Translocation of cytochrome c from
mitochondria to the cytosol is a crucial step in apoptosis
induced by Fas [10,21,22]. Once released, cytochrome c in
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interaction with the Apaf1/caspase-9 complex initiates an
apoptotic protease cascade [23].
These data clearly indicate that in many cells a strong rela-
tion exists between mitochondria and caspase activation in
apoptosis. To further investigate this relation, we tested
whether Percoll puri¢ed mitochondria treated with the PT-
inducing agent atractyloside release a caspase-processing ac-
tivity. Following detection of procaspase-11 processing, we
further puri¢ed this caspase-processing protease and charac-
terized it as cathepsin B.
2. Materials and methods
2.1. Reagents
Ac-YVAD.cmk was purchased from Calbiochem-Novabiochem
(San Diego, CA, USA). z-VAD.fmk, z-FA.fmk and z-DEVD.fmk
were supplied by Enzyme Systems Products (Dublin, CA, USA).
Atractyloside was purchased from Sigma (St. Louis, MO, USA) and
digitonin from Merck (Darmstadt, Germany). Bongkrekic acid (BA)
was kindly provided by Dr. Duine (Delft University, Delft, The Neth-
erlands). Anti-rat cathepsin B antibody was from Upstate Biotechnol-
ogy (Lake Placid, NY, USA) and anti-cytochrome c antibody from
PharMingen (San Diego, CA, USA).
2.2. Plasmids
The cloning of full-length murine CASP-1, CASP-2, CASP-3,
CASP-6, CASP-7, CASP-11, CASP-12 and CASP-14 and their sub-
cloning into pGEM11zf(+) (Promega Biotec, Madison, WI, USA) and
the preparation of the in vitro transcribed/translated proteins have
been described previously [24,25].
2.3. Cell lines and culture conditions
HeLa and L929 cells were grown in Dulbecco’s minimum essential
medium supplemented with 5% FCS and 5% NCS, at 37‡C under a
5% CO2 atmosphere.
2.4. Preparation of organelles
Mitochondria were isolated from Wistar rat hepatocytes (8 weeks,
male) as described in [26]. They were then further puri¢ed on a Percoll
gradient (Pharmacia Biotech, Uppsala, Sweden) as described in [27],
and were ¢nally washed and resuspended in cell free system (CFS)
bu¡er [17] and used immediately. Rat liver lysosomes were prepared
as described in [28]. Nuclei from HeLa cells were puri¢ed on a sucrose
gradient as described in [29] and conserved in 50% glycerol in NB
bu¡er at 320‡C for maximally 2 weeks.
2.5. Puri¢cation of the caspase-processing protease
All puri¢cation steps were carried out at 4‡C to avoid loss of bio-
logical activity. Percoll puri¢ed rat hepatocyte mitochondria were
treated with 5 mM atractyloside (Atr) to induce permeability transi-
tion. After centrifugation (100 000Ug), supernatant from these mito-
chondria was ¢rst separated by size exclusion chromatography on a
Superdex 75 FPLC column (Pharmacia Biotech) in CFS bu¡er. Active
fractions were pooled and loaded on a Mini Q Aº kta puri¢er column
(Pharmacia Biotech) that was pre-equilibrated with CFS bu¡er. Elu-
tion was performed with a linear gradient from 0 to 250 mM NaCl in
CFS bu¡er over 15 column volumes at 0.6 ml/min, followed by elu-
FEBS 21033 9-11-98 Cyaan Magenta Geel Zwart
Fig. 1. Cleavage of procaspase-11 by crude supernatant of Atr-
treated mitochondria. 35S-labeled in vitro transcribed/translated pro-
caspase-11 (indicated as procasp-11) was incubated with the respec-
tive samples as described in Section 2. Lower molecular weight
bands of procaspase-11 are presumably due to internal initiation
and/or premature termination. Processing was analyzed by 14%
SDS-PAGE. Processed products are indicated as the p20 and p10
subunits. Incubation time of the experiment shown was 30 min.
Longer incubation times of up to 1.5 h did not alter the cleavage
pattern. Lane a: Procaspase-11; lane b: procaspase-11+supernatant
of Atr-treated mitochondria; lane c: procaspase-11+supernatant of
non-treated mitochondria (note that some activity is observed here
as well, which is probably due to spontaneous leakage of the organ-
elles after isolation); lane d: procaspase-11+supernatant of Atr-
treated mitochondria pre-incubated for 15 min with z-VAD.fmk (2
WM); lane e: procaspase-11+caspase-8.
Fig. 2. Comparative 2-dimensional gel electrophoresis of the supernatant of Atr-treated and non-treated mitochondria reveals several di¡erential
protein spots. The crude supernatant was ¢rst separated by anion exchange on a Mono Q column (FPLC system, Pharmacia); proteins were
eluted with a linear gradient from 0 to 250 mM NaCl in CFS bu¡er over 15 column volumes. Fractions that contained caspase-processing ac-
tivity were pooled and compared with identical fractions from the supernatant of non-treated mitochondria. Protein spots were revealed by
high-sensitivity silver staining. Major di¡erential protein spots are indicated by an arrow.
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tion of 2 column volumes of 1 M NaCl in CFS bu¡er. Fraction
collection was started after 3 column volumes and fractions of 200
Wl were collected. Most of the proteins eluted in the ¢rst 20 fractions
of the gradient and the rest of the proteins eluted with 1 M NaCl. All
fractions were tested for their ability to process procaspase-11. Activ-
ity was present from fractions 7^15 with peak activity in fractions 11^
14 which corresponds to an NaCl concentration of 90^107 mM. Anal-
ysis of these fractions by 2-dimensional gel electrophoresis and silver
staining showed that fractions 9^11 contained only the 25^27-kDa
doublet, which was later identi¢ed as cathepsin B (fractions 9 and
10 contained only a very small amount of protein which was hardly
detectable by silver staining). Fractions 12^15 contained also a more
acidic isoform of the 25^27-kDa doublet and starting from fraction 13
other contaminating proteins became detectable.
To study the di¡erent activities of the caspase-processing protease,
fractions 11^13 were used. Identical fractions of a run with bu¡er only
were used as control.
2.6. Determination of the caspase-processing activity of the protease
35S-labeled caspases were prepared with an in vitro coupled tran-
scription/translation TNT kit from Promega Biotech, using SP6 or T7
RNA polymerase to transcribe genes cloned in pGEM11zf(+) and
pLT10TH vector, respectively [24]. The reaction products were ana-
lyzed by SDS-PAGE and stored at 370‡C until needed. Two Wl of
this material was incubated for 30 min at 37‡C with 2 Wl of the crude
supernatant or 2 Wl of the puri¢ed protease in a total volume of 20 Wl
CFS bu¡er. Cleavage products were analyzed by SDS-PAGE followed
by autoradiography or £uorography of the dried gels. In the case of
inhibitor studies, the puri¢ed protease was preincubated with inhibitor
for 15 min at 37‡C.
2.7. Two-dimensional gel electrophoresis (2-DE)
2.7.1. Isoelectro-focusing. Isoelectro-focusing was carried out on
18-cm IPG strips, pH 3^10 (Pharmacia, Uppsala, Sweden) according
to the instructions of the manufacturer. Samples in CFS bu¡er were
precipitated with acetone and redissolved in lysis bu¡er.
2.7.2. SDS-PAGE. The second dimension (SDS-PAGE) was run
on large horizontal Excell gradient gels 12^14% acrylamide (Pharma-
cia, Uppsala, Sweden) according to the instructions of the manufac-
turer.
2.8. Amino acid sequence analysis
Coomassie blue-stained 2-DE spots were digested in situ with modi-
¢ed trypsin (Promega) overnight at 37‡C. Peptides were recovered by
sonication in the presence of 0.1% SDS to facilitate e⁄cient peptide
extraction from the gel pieces. Peptides were separated by use of a
weak anion exchange pre-column (AX-300) in series with a reversed
phase column (ODS-300) using an ABI 173 HPLC system. Fractions
containing the resolved peptides were collected manually prior to Ed-
man sequencing on an ABI Procise high sensitivity system employing
capillary HPLC.
2.9. Western blotting
Proteins were separated by SDS-PAGE (14%) and transferred to
nitrocellulose. The blots were incubated with the desired antibody and
followed by ECL-based detection (Amersham Life Science, Amer-
sham, UK).
2.10. Determination of apoptogenic activity
L929 cells were plated on coverslips 2 days before the experiment.
Cells were permeabilized with 0.03% digitonin in CFS bu¡er for 3
min. The leaked out cytosol was removed by aspiration and cells
were washed with PBS bu¡er (37‡C). Freshly puri¢ed cathepsin B
in CFS bu¡er, pH 7.4, supplemented with 2 mM ATP was added
on top of the coverslip. After the appropriate incubation time at
37‡C, the cells were stained with propidium iodide (3 WM) and ana-
lyzed by confocal laser scanning microscopy (CLSM). Apoptogenic
activity on isolated nuclei and ladder formation were performed as
described in [30].
3. Results
3.1. Puri¢cation of a caspase-processing protease.
It is well documented that mitochondria that undergo per-
meability transition (PT) release apoptogenic factors into the
cytosol [15^17]. Accordingly, we tested whether treatment of
Percoll puri¢ed rat liver mitochondria with the PT-inducing
agent atractyloside (Atr) resulted in release of a caspase-proc-
essing activity. We tested the processing of in vitro tran-
scribed/translated murine procaspase-1, -2, -3, -6, -7, -11, -12
and -14 [24,25]. Since procaspase-11 was found to be the best
substrate for this caspase-processing protease, we have further
used its processing as activity assay to purify and identify this
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Fig. 3. Puri¢cation of the caspase-processing protease. A: The rele-
vant part of the elution pro¢le of the Mini Q column (Aº kta puri¢er,
Pharmacia) (mA.U stands for milli absorbance units). The separa-
tion was carried out as described in Section 2. The lower part of
the ¢gure shows the SDS-PAGE analysis of processing of procas-
pase-11 by the corresponding mini Q fractions. C is unprocessed
procaspase-11. B: The 2-dimensional gel electrophoresis protein pat-
tern of the most active fractions revealed by high-sensitivity silver
staining. The 25-kDa doublet that was identi¢ed by amino acid se-
quence analysis as cathepsin B, and the lower MW protein, presum-
ably the light chain of cathepsin B, are indicated by an arrow. To
study the di¡erent activities of the caspase-processing protease, frac-
tions 11^13 were used.
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caspase-processing protease. Fig. 1 shows the proteolytic ac-
tivity of the supernatant of the Atr-treated and non-treated
mitochondria on in vitro transcribed/translated procaspase-11.
As shown, in the presence of the Atr-treated sample procas-
pase-11 disappears (lane b), and this is accompanied by the
appearance of the p20 and p10 subunits, thus suggesting a
proteolytic maturation similar to the one generated by cas-
pase-8 treatment (lane e). The caspase-processing activity
present in the supernatant of Atr-treated mitochondria could
be completely inhibited by the broad-spectrum caspase inhib-
itor z-VAD.fmk (lane d) and iodoacetamide (not shown) sug-
gesting that it is a cysteine protease presumably belonging to
the caspase family.
To isolate and further characterize the protease responsible
for this activity, we employed high-resolution 2-dimensional
gel electrophoresis (2-DE). Comparison of the protein pattern
of the supernatant of the Atr-treated and non-treated mito-
chondria revealed high complexity and thus rendered interpre-
tation di⁄cult. Fractionation of the crude supernatant of Atr-
treated mitochondria by anion exchange chromatography on
a Mono Q column, followed by comparison of the protein
pattern of the fractions that contained procaspase-11 process-
ing activity with the corresponding fractions of the superna-
tant of non-treated mitochondria, revealed some major di¡er-
ential spots present in the Atr-treated sample (indicated by
arrows in Fig. 2). Among these, a double protein spot of
approximately 25 kDa was prominent. Further puri¢cation
of the proteolytic activity through size exclusion chromatog-
raphy on a Superdex 12 column, followed by anion exchange
chromatography on a high-resolution Mini Q column, showed
that proteolytic activity was present in 3 consecutive peaks
(Fig. 3A). Analysis of the most active fractions (9^15) by
high-resolution 2-DE and high-sensitivity silver staining re-
vealed that the 25-kDa doublet was the major component
present in these fractions. Fractions 9 and 10 contained only
the 25-kDa doublet but in very low amounts. Fig. 3B shows
the 2-DE pattern of fractions 11^14. Besides the 25-kDa dou-
blet, a more acidic isoform of the 25-kDa doublet could be
detected in fractions 12^15. Starting from fraction 13, more
contaminating proteins were present. The high activity present
in fractions 13 and 14 correlated with the higher concentra-
tion of the 25-kDa doublet. The presence of several isoforms
of the 25-kDa doublet could explain why the activity is dis-
tributed over several peaks. The more acidic isoform may be
generated either by phosphorylation or by proteolytic removal
of a small basic fragment. However, anti-phospho-tyrosine,
-serine or -threonine antibodies failed to react with the pro-
tein, thus rendering phosphorylation unlikely. The observa-
tion that the more acidic isoform is present when size exclu-
sion chromatography is combined with anion exchange
chromatography but is absent when only anion exchange
chromatography is carried out, suggests that the acidic iso-
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Fig. 3 (continued).
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form is generated during gel ¢ltration presumably through
autoprocessing.
3.2. The caspase-processing protease is identical to cathepsin B
Amino acid analysis of peptides generated by in situ gel
trypsin digest on Coomassie blue-stained protein spots, iden-
ti¢ed the protease as cathepsin B (a list of peptides sequenced
is given in Table 1). This was con¢rmed by Western blotting
using a polyclonal antibody against rat cathepsin B. Fig. 4
shows a silver staining of the partially puri¢ed protease (A)
and the corresponding Western blot (B). Cathepsin B exists as
a 40-kDa proform and a 30-, 27- and 25-kDa mature protein.
Our puri¢ed cathepsin B represents the two-chain form which
is composed of the 25/27-kDa chain and a smaller 5000-Da
chain (presumably corresponding to the low molecular weight
protein spot indicated by an arrow in fractions 12, 13 and 14
of Fig. 3B) that are held together by a disul¢de bond [31]. The
two-chain form is equally active as the single-chain 30-kDa
form. The presence of the two isoforms could be due to a
di¡erence in the dipeptide which is normally lost during pro-
teolytic processing into the two-chain form [31].
Commercially available cathepsin B (Sigma) processed pro-
caspase-11 (in CFS bu¡er at pH 7.4) exactly as our puri¢ed
cathepsin B did. The p20 and p10 subunits generated by the
former also had an identical molecular weight, as judged from
their electrophoretic mobility, as those generated by caspase-8
(data not shown).
Since cathepsin B is known to be an abundant lysosomal
protein and since Atr, which releases cathepsin B from the
mitochondrial preparations, is known as a speci¢c ligand of
the mitochondrial adenine nucleotide translocator, we further
investigated whether cathepsin B was derived from the mito-
chondria or from a minor lysosomal contamination present in
mitochondrial preparations. Confocal laser scanning micro-
scopy using the anti-rat cathepsin B antibody on a mouse
hepatoma cell line failed to detect any cathepsin B in mito-
chondria while a clear lysosomal staining was visible (data not
shown). Furthermore, bongkrekic acid which acts as a stable
inhibitor of PT, prevented the Atr-induced release of cyto-
chrome c from the intermembrane space of the mitochondria,
but did not inhibit the release of cathepsin B (data not
shown), indicating that cathepsin B is derived from a lysoso-
mal contamination. This contamination is, however, very mi-
nor since we could not detect cathepsin B, one of the most
abundant lysosomal proteins, by Western blotting using 200
Wg protein of the mitochondrial preparation. In addition,
atractyloside also induced the release of cathepsin B from
puri¢ed lysosomes (Fig. 5).
3.3. Cleavage of caspases by cathepsin B
Since we previously observed cleavage of several caspases
with the crude supernatant of Atr-treated mitochondria, we
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Fig. 5. Atractyloside induces the release of cathepsin B from puri-
¢ed lysosomes. Supernatant (16 Wg of protein) from Atr- and con-
trol-treated lysosomes was analyzed for the presence of cathepsin B
by Western blot analysis.
Fig. 4. Immunostaining of cathepsin B on a partially puri¢ed fraction of the caspase-processing protease. To obtain a partially puri¢ed fraction
of the protease, crude supernatant of Atr-treated mitochondria was separated by anion exchange chromatography on a Mini Q column (Phar-
macia). Active fractions were pooled and 75% of the material was used for silver staining and the other 25% for the immunostaining. A: Silver
staining of a 2-dimensional gel of the partially puri¢ed caspase-processing protease (indicated by an arrow). B: The corresponding immuno-
staining with anti-rat cathepsin B. Note that the horizontal distance between the cathepsin B spots is smaller in the immunostaining; this is
due to the di¡erent processing of the gels. The lower molecular weight protein spots that are also recognized by the anti-cathepsin B antibody
are presumably degradation products of cathepsin B.
Table 1
Amino acid sequence analysis of peptides derived from the caspase-





The numbers indicate the positions of the amino acid residues in the
sequence of rat cathepsin B.
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tested whether this was also the case for puri¢ed cathepsin B.
All experiments were done with freshly puri¢ed cathepsin B,
since it was found to be considerably more biologically active
than the commercial preparation. For example, we obtained
complete processing of procaspase-11 with freshly puri¢ed
cathepsin B at concentrations of 2^5 Wg/ml (the concentration
was estimated from the UV absorbance on the Mini Q column
using commercial cathepsin B as a reference), while we could
not obtain complete processing with the commercial prepara-
tion at a concentration of 30 Wg/ml. This means that our
puri¢ed cathepsin B is at least 6-fold more biologically active
than the commercial preparation.
In agreement with our previous results using crude super-
natant, we found that procaspase-11 is most e⁄ciently proc-
essed into its p20 and p10 subunits by cathepsin B (Fig. 5).
Furthermore, the processed form generated by cathepsin B is
biologically active (Schotte et al., submitted). Also caspase-1
(without prodomain) was readily cleaved by cathepsin B,
which is not surprising since caspase-1 is highly homologous
to caspase-11. To the contrary, procaspase-2, -6, -7 and -14
were only weakly processed while procaspase-3 was found to
be a very poor substrate (Fig. 5). The processing of procas-
pase-3 corresponds with the removal of the prodomain since
caspase-3 without prodomain was not cleaved by cathepsin B
(Fig. 5). Finally, procaspase-12 was not processed by cathep-
sin B, indicating that it is not a substrate for the protease.
3.4. Cathepsin B is inhibited by synthetic peptide caspase
inhibitors
Since cathepsin B has caspase-processing activity and since
the broad spectrum caspase inhibitor z-VAD.fmk could inhib-
it the caspase-processing activity present in the crude super-
natant of Atr-treated mitochondria, we tested whether puri-
¢ed cathepsin B was sensitive to the synthetic caspase
inhibitors. As shown in Fig. 6, the proteolytic processing of
procaspase-11 by cathepsin B was completely inhibited by the
broad spectrum caspase inhibitor z-VAD.fmk and the casp-
ase-3 inhibitor z-DEVD.fmk at concentrations of 2 WM, but
not by the caspase-1 inhibitor Ac-YVAD.cmk (2 WM). Ac-
YVAD.cmk inhibited only partially at a concentration of 50
WM. Also, puri¢ed cathepsin B is inhibited by the speci¢c
cathepsin B inhibitor z-FA.fmk and leupeptin.
3.5. Cathepsin B has apoptogenic activity
Nuclear chromatin condensation and DNA fragmentation
are considered to be the hallmark of apoptosis. Therefore, we
tested whether our puri¢ed cathepsin B had apoptogenic ac-
tivity on nuclei. Digitonin-permeabilized cells from which the
cytosol was removed were incubated with freshly puri¢ed
cathepsin B (5 Wg/ml, estimated as described above), stained
with propidium iodide and analyzed by CLSM for occurrence
of nuclear changes indicative of nuclear apoptosis. Already
after 15 min of incubation cathepsin B induced chromatin
condensation in all nuclei (Fig. 7). After 30 min of incubation
most of the nuclei had an irregular shape (shrinkage) and
their DNA content was drastically reduced as judged from
£uorescence intensity. Both features of nuclear apoptosis ^
chromatin condensation and DNA fragmentation ^ were
abolished when cathepsin B was preincubated with z-VAD-
fmk. Cathepsin B-induced DNA degradation in propidium
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Fig. 7. Inhibition by synthetic peptide caspase inhibitors of procas-
pase-11 processing by puri¢ed cathepsin B. Puri¢ed cathepsin B was
preincubated with the following inhibitors (2 WM; * 50 WM) for 15
min at 37‡C. zV, z-VAD.fmk; zD, z-DEVD.fmk; zY, Ac-
YVAD.cmk; zF, z-FA.fmk; L, leupeptin.
Fig. 6. Processing of caspases by puri¢ed cathepsin B. [35S]Methionine-labeled in vitro transcribed/translated caspases (2 Wl) were incubated (30
min, 37‡C) either with CFS bu¡er (3) or with 10 Wl of puri¢ed cathepsin B (+) in a total volume of 20 Wl. Processed products were analyzed
by SDS-PAGE (14% acrylamide) and are indicated by arrowheads in the ¢gure. The higher molecular weight of caspase-3 without prodomain
is due to the presence of an N-terminal His6-tag and a C-terminal Strep-tag.
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iodide-stained digitonin-permeabilized cells was also observed
by £ow cytometry (data not shown). Cathepsin B also induced
chromatin condensation and DNA degradation on isolated
nuclei from HeLa cells ; agarose gel electrophoresis followed
by ethidium bromide staining showed a typical DNA ladder
(data not shown).
4. Discussion
In this study, we identi¢ed the lysosomal protease cathepsin
B as an activator of caspase zymogens in vitro. Cathepsin B
was puri¢ed from the supernatant of a Percoll puri¢ed rat
liver mitochondrial preparation that was treated with the PT
inducing agent atractyloside which is known as a ligand for
the mitochondrial adenine nucleotide translocator (ANT).
The puri¢ed protease corresponded to the 25^27-kDa form
which represents the heavy chain of the two-chain lysosomal
form of the enzyme [32]. The 25^27-kDa doublet is most likely
due to di¡erences in carbohydrate modi¢cation [32]. Also the
light chain of approximately 5 kDa was present in the prep-
arations. All activities observed with the crude supernatant,
namely selective cleavage of caspases and induction of nuclear
apoptosis, were similarly observed with puri¢ed cathepsin B
(Fig. 8). Apparently, no additional caspase-processing activity
was present in the supernatant. Since the cathepsin B released
was found to be of lysosomal origin, these results indicate that
mitochondria which undergo PT do not release proteases that
directly activate caspases. These results also indicate that ei-
ther Atr is not speci¢c for the adenine nucleotide translocator
in the mitochondria or that maybe similar proteins are located
in the lysosomal membrane.
Murine procaspase-11 was found to be the best substrate
for cathepsin B. The p20 and p10 subunits from caspase-11
generated by cathepsin B were identical to those generated by
caspase-8. Processed caspase-11 was biologically active as
measured by activation of procaspase-3, followed by measure-
ment of the latter by cleavage of the £uorogenic substrate Ac-
DEVD.amc (Schotte et al., submitted). Cathepsin B generated
only the speci¢c p20 and p10 subunits at neutral pH (pH 7.4),
while more acidic or more basic pH resulted in an almost
complete degradation of procaspase-11. Caspase-1 was also
processed, though to a lesser extent than procaspase-11. Pro-
caspase-2, -6, -7 and -14 were weak substrates for cathepsin B
and procaspase-3 was a very poor substrate.
Cathepsin B has exo- as well as endo-peptidase activity. The
endopeptidase activity of cathepsin B prefers, but is not lim-
ited to, a basic and hydrophobic amino acid at the P1 and P2
substrate sites, respectively. Such a preferred site is present in
murine procaspase-11 (residues 264-IR-265) and in murine as
well as in human caspase-1 (residues 295 and 296, respec-
tively). These residues are conserved and are just N-terminal
of the preferred Asp-Xaa cleavage site between the p20 and
p10 subunit [33]. The region N-terminal of the p20 in murine
procaspase-11 also contains a preferred site (61-MK-62) for
cathepsin B and is located within the predicted Asp-Xaa res-
idues that separate the prodomain from the p20. Caspase-11
and caspase-1 belong to the class of initiator caspases, while
caspase-3 is an executioner. Thus, given the speci¢city of ca-
thepsin B for caspase-11 and caspase-1 and not for caspase-3,
cathepsin B may play a regulatory role in the activation of
initiator caspases rather than executioner caspases.
Questions remain open as to how cathepsin B itself is acti-
vated during apoptosis and other caspase-dependent processes
such as the maturation of pro-IL 1L and whether caspase
processing occurs in the lysosomes or in the cytosol. However,
our observation that the speci¢c p20 and p10 subunits of
procaspase-11 are generated only at neutral pH indicates
that activation most likely occurs in the cytosol. The mecha-
nism through which cathepsin B is released from the lyso-
somes also remains an open question. It has been reported
that photo-oxidative damage of the lysosomal membrane ini-
tially results in disruption of the lysosomal proton-gradient
and later in disruption of the lysosomal membrane [34]. Fur-
thermore, severe photo-oxidation, which results in severe ly-
sosomal damage, causes necrosis, whereas moderate stress re-
sults only in partial lysosomal leakiness with release of
apoptosis-inducing proteases which then leads to apoptosis.
Therefore, lysosomes could function as a sensor/e¡ector of
oxidative stress induced by certain stimuli and might ful¢ll a
similar role to that of mitochondria in apoptosis.
Our results obtained with an open cell system (namely dig-
itonin-permeabilized cells from which the cytosol was re-
moved) but also with isolated nuclei indicate that cathepsin
B also induces nuclear apoptosis. Accordingly, no additional
cytoplasmic factors are required for this activity. Cathepsin B
has no nuclease activity by itself and therefore must directly
or indirectly activate a nuclease through proteolytic cleavage.
A plausible candidate is the recently described ‘inhibitor of
caspase activated deoxyribonuclease’ (mouse ICAD, which is
homologous to human DFF45) which is cleaved by caspase-3
[35]. This cleavage results in activation and translocation of
CAD to the nucleus. However, the complex ICAD-CAD is
cytoplasmic, while cathepsin B induces nuclear apoptosis in
isolated nuclei. Therefore, the ICAD-CAD complex and pos-
sibly other proteins should remain associated with the isolated
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Fig. 8. Induction of nuclear apoptosis by puri¢ed cathepsin B. Digi-
tonin-permeabilized L929 cells were incubated at 37‡C with CFS
bu¡er (A), puri¢ed cathepsin B for 15 min (B) and 30 min (C) or
puri¢ed cathepsin B preincubated with 2 WM z-VAD.fmk (D).
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nuclei in order to mediate nuclear apoptosis under this con-
dition, a feature that is not supported by the available data.
Also, analysis by 2-dimensional gel electrophoresis of cathep-
sin B-treated (3 min) nuclei from L929 cells revealed a protein
spot in the basic region of the gel that speci¢cally disappeared
in the cathepsin B-treated sample. The estimated pI value of
this protein spot is 8.0, while mouse ICAD has a pI of 4.5,
thus indicating that cathepsin B-induced nuclear apoptosis is
not mediated through cleavage of ICAD.
Translocation of cathepsin B from the cytoplasm to the
nucleus has been shown during bile-salt induced hepatocyte
apoptosis [36]. This indicates the possibility for a direct role of
cathepsin B in the nucleus in at least some forms of apoptotic
cell death. The reason why several proteases such as caspases,
but also other cystein proteases, such as cathepsin B and D
and some serine proteases (our own unpublished observation)
can induce nuclear apoptosis could be ascribed to the fact that
protease-sensitive regions in the nucleases or in their activa-
tors or inhibitors that need to be cleaved during apoptosis are
susceptible to various kinds of proteases.
Several lines of research pinpoint a role for cathepsin B as
intracellular protease in active cell death or apoptosis. It has
been shown that cathepsin B plays a role in apoptosis of
luminal epithelial cells of the prostate and mammary gland
that occurs after hormone ablation [37]. An increased expres-
sion of cathepsin B is observed in apoptotic cells and the
protein was subsequently localized in the apoptotic bodies.
Moreover, a recent immunohistochemical study in in¢ltrative
breast carcinomas of the natural cysteine protease inhibitor
cystatin A, which inhibits cathepsin B and also cathepsin H, L
and S, suggests a role for cathepsins in breast cancer regres-
sion: tumors positive for cystatin A are of larger size and have
higher mitotic activity than cystatin A-negative tumors [38].
Cystatin A expression also correlates with negative staining
for the anti-apoptotic protein Bcl-2. These ¢ndings suggest
that the decreased apoptosis observed in tumors that express
cystatin A could be due to cystatin A-mediated inhibition of
cathepsin B and/or other cathepsins. Still another line of re-
search points to a role for cathepsin B in 1,25-dihydroxyvita-
min D3 (1,25(OH)2D3)-induced apoptosis. 1,25(OH)2D3 in-
hibits breast cancer cell growth both in vivo and in vitro.
MCF7 cells treated with 1,25(OH)2D3 exhibit upregulation
of proteins associated with mammary gland regression,
namely clusterin and cathepsin B, and downregulation of
Bcl-2 [39], thus indicating that increased sensitivity to apop-
tosis might be correlated with the presence of cathepsin B. In
conclusion, our results provide a molecular basis for the ap-
parent link between apoptosis and cathepsin B, namely
through a cathepsin B-initiated activation of the caspase cas-
cade resulting in activation of executioner caspases.
Both newly described activities, namely cleavage of caspase
zymogens and induction of nuclear apoptosis by cathepsin B,
are inhibited by the broad spectrum caspase inhibitor z-
VAD.fmk (2 WM), the caspase-3 inhibitor z-DEVD.fmk (2
WM) and, albeit to a lesser extent, by the caspase-1 inhibitor
Ac-YVAD.cmk (partial inhibition at 50 WM). This means that
the latter inhibitors can no longer be classi¢ed as speci¢c
caspase inhibitors. As a consequence, in vivo results obtained
with these inhibitors have to be interpreted with caution.
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